HLA-Dependent Risk of T-cell Response to Micro-Dystrophin Transgene Product in Patients with DMD Harboring Mutations in Dystrophin N-terminal Region and Treated with AAV-based Gene Therapies
Time: 9:30 am
day: Conference Day Two
Details:
- In silico and ex vivo investigations to understand the SAEs of immune-mediated myositis in DMD clinical trials
- Assessment of HLA-dependent immunogenicity risks
